[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100483595":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":20,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":28,"acronym":29,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":33,"enrollmentInfo":34,"targetDuration":37,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"AZ Sint-Jan AV","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TEER",null,"Patients with tricuspid valve regurgitation eligible for transcatheter edge-to-edge repair (TEER)",[13],"Procedure: Transcatheter edge-to-edge repair (TEER)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"PROCEDURE","Transcatheter edge-to-edge repair (TEER)","Minimally invasive transcatheter-based edge-to-edge repair technique for tricuspid regurgitation",[9],{"type":21,"investigatorFullName":22,"investigatorTitle":23,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Jan Van der Heyden","Principal Investigator","100483595","tribel-registry-national-belgian-registry-of-percutaneous-tricuspid-valve-repair-using-a-transcatheter-edge-to-edge-repair-technique-100483595",false,"NCT05577078","TriBEL Registry: National Belgian Registry of Percutaneous Tricuspid Valve Repair Using a Transcatheter Edge-to-edge Repair Technique","TriBEL","Inclusion Criteria:\n\n* At least 18 years old\n* Eligible for TEER procedure\n* Informed consent signed\n\nExclusion Criteria:\n\n* Unwilling to provide informed consent","ALL","18 Years","110 Years",{"count":35,"type":36},120,"ESTIMATED","5 Years","OBSERVATIONAL","In this study, patients who have undergone or will undergo a transcatheter edge-to-edge repair (TEER) for tricuspid valve regurgitation (TR) will be followed up for 5 years. The goal of this prospective and retrospective, observational, non-randomized, multicenter registry is to confirm that TEER is a feasible, safe and effective treatment option for TR and to evaluate the long-term efficacy and safety of TEER.\n\nThe main endpoints are:\n\n* Change in tricuspid regurgitation grade: number of patients with a reduction in tricuspid regurgitation score by at least one grade\n* Composite of major adverse event: number of patients with composite of major adverse event (cardiovascular mortality, acute kidney injury, myocardial infarction, stroke or TIA, coronary revascularization, new onset AF or ventricular arrhythmia)",[41],"Tricuspid Valve Regurgitation","NOT_YET_RECRUITING","2022-10-10",{"date":45,"type":46},"2022-10-13","ACTUAL",{"date":48,"type":36},"2023-01-01",{"date":50,"type":36},"2029-12-31",{"name":5,"class":6}]